A €375M IPO from Evotec was the highlight of European biotech investments in November, with other cash going to firms working on cell therapy reprogramming and immuno-oncology.
The total biotech investment haul for European companies reached €1.2B in November, with 41 deals in the bag. These deals included European and Israeli companies launching a private round or initial public offering (IPO).
November’s total investment catch was double that of October. This was partly because November saw four IPOs totaling €514.7M, while October had only one €15.5M IPO by the firm Acticor Biotech.
The German giant Evotec made the headlines with a colossal Nasdaq IPO worth €375.4M. The firm has a diverse business model that includes developing a drug pipeline, providing drug discovery services, and investing in other companies.
Other major IPOs were closed by IO Biotech and MaaT Pharma in Denmark and France respectively. IO Biotech is developing a cancer immunotherapy while MaaT Pharma is on the cutting edge of the European microbiome field,
The post The Top European Biotech Investment Rounds in November appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
Published on Wed, 08 Dec 2021 00:14:17 +0000 and brought to you by Apptigent PowerTools